Adrian Newman-Tancredi
is co-founder and
Chief Scientific Officer
of Neurolixis Inc.

Find out more here.

 

News

Adrian Newman-Tancredi PhD DSc will be participating in an online neuroscience conference taking place from 18th to 20th June 2013. The webinar, organized by the online life-science...Read More
Dr Newman-Tancredi gave a lecture on Monday 27th May at the Dopamine 2013 meeting in Alghero, Sardinia. The congress was attended by over 300 researchers specializing in the study...Read More
Dr. Adrian Newman-Tancredi has been awarded a D.Sc. (“Higher Doctorate”) by the University of Kent at Canterbury in recognition of his “original contribution to the...Read More

NeuroAct Communication offers independent consulting in neuropharmacology and preclinical drug discovery to
bioscience companies, agencies and the investment community.

 
  •  

     

     

    NeuroAct Communication

    offers professional and independent advice

    at each stage of early CNS drug discovery. 

     

    Find out about Consulting Services

    For more information, Contact

  •  

    Newsletter

    Newsletters informing of advances in NeuroAct Communication's

    activities are sent to subscribers on an occasional basis. 

     


     

    Read the latest newsletters:

    June 2013

    January 2013

  •  

     

     

    NeuroAct Communication  

    was founded by Adrian Newman-Tancredi PhD DSc

    an experienced industrial neuropharmacologist.

     

    Find out about Adrian in his Executive Profile

    Read his colleagues' Endorsements

  •  

      

    Expertise in CNS Drug Discovery

    NeuroAct Communication offers expertise in preclinical 

    CNS pharmacology of antipsychotics, antidepressants, analgesics.   

    Read more

    ClozapineF-15599Milnacipran

  •  

     

    Watch WEBCASTS OF Adrian's lectureS

    Adrian Newman-Tancredi PhD DSc gives lectures to a
    variety of academic and industrial audiences.

    Watch Webcasts of his lectures on YouTube:

     

    Pharmacology of antipsychotics (Amsterdam, 2010)

    Serotonin "biased agonists" (Vienna, 2012)